Literature DB >> 30176223

Geniposide suppresses growth, migration and invasion of MKN45 cells by down-regulation of lncRNA HULC.

Ji Ma1, Yong Ding2.   

Abstract

Gastric cancer (GC) is a serious disease with high incidence rate and high mortality. Geniposide (GEN) exhibits multiple biological properties including anti-tumor function. However, effect of GEN on GC is not well studied. Hence, the effects of GEN on GC were investigated in our study. HULC expression in GC tissue and GC cell lines (MKN45, SGC-7901, MKN28, AGS) was detected by qRT-PCR. Cell viability, colony formation, migration, invasion and cell apoptosis were examined by CCK-8 assay, survival fraction assay, modified two-chamber migration assay, Millicell Hanging Cell Culture and flow cytometry analysis, respectively. The expression of matrix metalloproteinase (MMP)-2/9 and vimentin was detected by qRT-PCR and western blot, respectively. The expression of PI3K/AKT and JNK was measured by western blot. The expression of HULC was up-regulated both in GC tissue and cell lines (P < .05, P < .01 or P < .001). GEN negatively regulated the expression of HULC in MKN45 cells (P < .05 or P < .01). GEN decreased cell viability (P < .05), colony formation (P < .01), migration (P < .05) and invasion (P < .05) while HULC overexpression led to the opposite results in GEN-treated cells. The expression of phosphatidylinositol 3' -kinase (PI3K)/ protein kinase B (AKT) and c-Jun N-terminal kinase (JNK) was down-regulated by GEN (all P < .05) while reversed by HULC overexpression. HULC was up-regulated in GC. GEN inhibited MNK45 cell viability, colony formation, migration and invasion while induced cell apoptosis by down-regulation of HULC in MKN45 cells. GEN inactivated PI3K/AKT and JNK signal pathways through down-regulation of HULC.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Gastric cancer; Geniposide; HULC; JNK; PI3K/AKT

Mesh:

Substances:

Year:  2018        PMID: 30176223     DOI: 10.1016/j.yexmp.2018.08.011

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   4.401


  7 in total

1.  Geniposide attenuates early brain injury by inhibiting oxidative stress and neurocyte apoptosis after subarachnoid hemorrhage in rats.

Authors:  Xiaolan Xiao; Shuangxi Sun; Yingbin Li; Xuecheng Cen; Shibiao Wu; Aili Lu; Jun Cai; Junjie Zhao; Shaoxue Li
Journal:  Mol Biol Rep       Date:  2022-04-26       Impact factor: 2.742

Review 2.  Updated Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of Natural Product Geniposide.

Authors:  Liping Liu; Qin Wu; Yuping Chen; Guoxiang Gu; Runan Gao; Bo Peng; Yue Wang; Anbang Li; Jipeng Guo; Xinru Xu; Xiaochen Shao; Lingxing Li; Ya Shen; Jihu Sun
Journal:  Molecules       Date:  2022-05-21       Impact factor: 4.927

Review 3.  Targeting PI3K in cancer: mechanisms and advances in clinical trials.

Authors:  Jing Yang; Ji Nie; Xuelei Ma; Yuquan Wei; Yong Peng; Xiawei Wei
Journal:  Mol Cancer       Date:  2019-02-19       Impact factor: 27.401

4.  LncRNA HULC Polymorphism Is Associated With Recurrent Spontaneous Abortion Susceptibility in the Southern Chinese Population.

Authors:  Zhenzhen Fang; Yanfang Yang; Yufen Xu; Hanran Mai; Wanqi Zheng; Lei Pi; Lanyan Fu; Huazhong Zhou; Yaqian Tan; Di Che; Xiaoqiong Gu
Journal:  Front Genet       Date:  2019-10-04       Impact factor: 4.599

5.  Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis.

Authors:  Linjun Hu; Junjun Zhao; Yang Liu; Xin Liu; Qiliang Lu; Zhi Zeng; Lifen Zhu; Xiangmin Tong; Qiuran Xu
Journal:  Int J Med Sci       Date:  2020-09-23       Impact factor: 3.738

6.  Research Progress and Application Prospects of Long Noncoding RNAs in Gastric Neoplasms.

Authors:  Bibo Tan; Fang Li; Zihao Chen; Yong Li
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

7.  Geniposide Alleviates Glucocorticoid-Induced Inhibition of Osteogenic Differentiation in MC3T3-E1 Cells by ERK Pathway.

Authors:  Baocheng Xie; Jiahuan Wu; Yongmei Li; Xuejun Wu; Zhanwei Zeng; Chenhui Zhou; Daohua Xu; Longhuo Wu
Journal:  Front Pharmacol       Date:  2019-04-18       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.